"there are people on this board waaaaaaaaaaaaaaay longer than you." And that is relevant why?
"The stock was trading around $12.00 less than a year ago, which is more than a double at this point by my math"
Congrats, you can multiply! Stock price aside, does management have the ability to run this public company efficiently and PROFITABLY? The jury is still out on that imo. Good luck!
super intelligent post there diejour44, when anyone with a slightly larger than pea sized brain can tell I'm not a short lol
"is 100m enough"? Maybe not but without the most recent public offering they already had 200m in cash. Is that enough?
"then to expand the test scope, to cover more for African American population"
I didn't know the current label on the box reads "for caucasians only"
SHOW ME you can run your company efficiently, sell your currently FDA approved and Medicare paid for product and TURN A PROFIT!! TURN A PROFIT!! TURN A PROFIT!! DO YOU UNDERSTAND WHAT I"M SAYING? lol THEN issue a few shares (if you still needed to) AND (probably at a much higher stock price)
If "ifs" and "buts" were candy and nuts........I just feel they're getting ahead of themselves. Everybody says hey! they can take this extra 100m and do this and that, advance this and buy them. Well, EXAS has what seems like the greatest thing since sliced bread so why not refrain for a few yrs from diluting shareholders and just concentrate on selling your currently FDA approved and Medicare paid for product.....rake in 200-300m? By then the stock price might be double what it is today. I just feel doing what they did in the last few days is planning for failure ya know "just in case".
If they can't make it with Colonguard the I doubt I stick around to give them another chance. Surely someone can understand my reasoning?
Yes, but depleted at what rate? 50m per yr? That's a good 3+ yrs worth of cash on hand? I know its cutting it close but, have some confidence and some cahones that your product is going to be successful, like I hear when the ceo does an interview! I guess in today's world we do pre bailouts now right?
200m in cash and a FDA approved medicare paid product selling now but hey, its easier just to dilute shareholders. Isn't 200m enough?
How about running the co efficiently, selling your FDA approved and Medicare priced product, saving your cash and taking things one step at a time WITHOUT diluting shareholders? Sell your gd product,bring in cash don't use your shareholder as a #$%$ pole! At any rate, I'm starting to realize why the short interest is so high. Oh well, just another company tha is run without the public shareholders in mind. Puke
•Named 2014 "Most Wired" health care organization by the American Hospital Association - the eleventh time since 1999
•Named top health care supply chain operation in the world, just second overall to Cardinal Health
By the Numbers
(Fiscal Year 2013):
•Acute Care Hospitals: 34
•Specialty Hospitals: 11 (includes heart, children's, rehab and orthopedic facilities)
•Clinic and Outpatient Facilities: 700
•Service Area: Arkansas, Kansas, Missouri, Oklahoma
•Outreach Ministries: Louisiana, Mississippi, Texas
•Fifth largest Catholic health care system in the U.S.
•Twentieth largest non-profit health care system in the U.S.
•Acute Licensed Beds: 4,231
•Mercy Clinic Physicians: over 2,100
•Acute Inpatient Discharges: 158,768
•Surgeries (Inpatient and Outpatient): 150,595
•Emergency Visits: 650,702
•Outpatient Visits: 8,361,683!!!!!!!!!!!!
•Operating Revenue: $4.48 billion
•Assets: $5.8 billion
•Traditional Charity Care: $116.6 million
•Unreimbursed Medicaid: $62.3 million
•Other Community Benefits: $40.6 million
Pursuant to the Second GS Amendment, Regeneron and Goldman Sachs have agreed to reduce the remaining number of warrants held by Goldman Sachs by up to 493,229, or 48.9%, for an aggregate amount payable by Regeneron not to exceed $148.5 million. The reduction in the number of warrants will be determined based on the number of warrants with respect to which Goldman Sachs has closed out its hedge positions during the period starting on November 26, 2014 and ending no later than February 12, 2015 (the "Transaction Period"). The payment amount will be based on the volume-weighted average of the per share prices at which Goldman Sachs purchases shares of Regeneron common stock, par value $0.001 per share, in order to close out its hedge positions in respect of such warrants during the Transaction Period, and will be due on the third business day following the last day of the Transaction Period.
Together, do Sanofi and Bayer hold 51% or more? If not, AMGN can bid for 51% and take control could they not? A 40% premium might un difficult things no?
Novartis makes Lucentis correct? Why would a behemoth like AMGN not want to enter the market and compete using Eylea? The statement " the lucentis / eylea issue would be difficult based on market share' is confusing can you please elaborate? Plus all the other possible blockbusters REGN is a part of and take care of the patent infringment claim concerning hypercholesterolemia/monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9).
"CYBR is useless if the malware or insider does not need credentials to complete the objective. Everyone is so
hyped on CYBR but does not understand its role and what it can actually do."
Fortunately for CYBR, currently, THAT IS HOW THE HACKERS ARE STEALING THEIR INFORMATION DUH